TAK
Takeda Pharmaceutical Co Ltd
17.40$
-0.1%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Cash Flow
Takeda Pharmaceutical Co Ltd (TAK) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2026), "Operating Cash Flow" came in at 1,041,431 million JPY. Tick rows to compare them in a chart.
All figures in millions of JPY.
Tick rows to compare them in a chart (up to 4)
| Line item | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 158,962 | 212,662 | 240,586 | 263,449 | 311,122 | 295,539 | 373,575 | 209,280 | 292,496 | 326,273 | 381,168 | 326,938 | 336,570 | 332,579 | 148,720 | 182,517 | 25,491 | 261,363 | 377,854 | 328,479 | 669,752 | 1,010,931 | 1,123,105 | 977,156 | 716,344 | 1,057,182 | 1,041,431 | |
| 33,364 | 33,605 | 28,430 | 29,962 | 28,083 | 31,226 | 28,728 | 28,820 | 31,690 | 118,081 | 114,825 | 106,722 | 150,194 | 247,206 | 215,743 | 260,951 | 197,381 | 171,426 | 182,127 | 247,691 | 583,649 | 559,671 | 583,151 | 664,400 | 728,002 | 761,396 | 721,127 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -213,777 | 20,350 | 14,714 | 15,385 | 18,610 | 20,084 | 29,122 | 37,663 | 43,374 | 60,672 | 70,871 | 72,867 | 72,775 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -387 | 30,359 | -67,011 | -25,372 | -49,042 | -75,330 | -200,526 | 169,881 | 21,003 | – | – | – | |
| -5,413 | -35,042 | 3,658 | 6,721 | -16,262 | -28,612 | -10,014 | -35,859 | -8,711 | -36,917 | 14,148 | -9,160 | 64,725 | -12,922 | -53,129 | 262,326 | -267,213 | 29,675 | 13,404 | 63,977 | 94,672 | 275,781 | 98,605 | -25,264 | -256,003 | -59,372 | 199,905 | |
| 35,423 | 26,941 | 37,523 | 33,477 | 54,160 | 53,669 | 32,093 | 29,151 | 32,618 | 39,464 | 86,960 | 124,165 | 71,042 | 112,259 | 78,519 | 108,718 | 84,857 | 112,027 | 128,262 | 134,114 | 217,710 | 236,468 | 186,037 | 633,689 | 480,730 | 379,625 | 414,659 | |
| -51,675 | -58,249 | 125,239 | 140,148 | -139,322 | -72,305 | 6,566 | 116,392 | 101,749 | -767,256 | -117,521 | -99,255 | -1,093,964 | -131,077 | -154,057 | 91,347 | -71,208 | -655,691 | -93,342 | -2,835,698 | 292,119 | 393,530 | -198,125 | -607,102 | -463,862 | -367,060 | -369,141 | |
| 28,009 | 36,610 | 48,541 | 54,435 | 60,869 | 74,958 | 85,529 | 98,757 | 129,167 | 142,446 | 143,554 | 142,055 | 142,013 | 142,118 | 142,133 | 141,637 | 141,538 | 141,688 | 141,893 | 142,952 | 282,582 | 283,357 | 283,665 | 279,416 | 287,188 | 302,498 | 311,901 | |
| – | – | – | – | – | -166 | -156 | -213,734 | -128,758 | -280,268 | -34 | -50 | -16 | -24 | -37 | -17,587 | -22,346 | -23,117 | -18,756 | -1,172 | -3,737 | -2,141 | -77,531 | -26,929 | -2,326 | -51,860 | -51,603 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -995 | 45,917 | 471,421 | -153,136 | 3,161,504 | -586,090 | -660,504 | -600,477 | -285,071 | 1,513 | -314,314 | 1,076 | |
| -27,907 | -41,910 | -52,658 | -58,990 | -59,344 | -73,912 | -89,290 | -315,942 | -262,082 | -425,840 | -148,046 | -146,544 | 393,789 | -152,202 | 96,502 | -300,998 | -124,839 | 289,896 | -326,226 | 2,946,237 | -1,005,213 | -1,088,354 | -1,070,265 | -709,148 | -354,416 | -751,425 | -496,820 | |
| 77,957 | 119,757 | 336,641 | 324,642 | 53,126 | 188,240 | 361,911 | 21,459 | -34,454 | -855,158 | 94,398 | 20,230 | -418,463 | 91,333 | 120,468 | -10,805 | -203,817 | -131,971 | -46,730 | 407,120 | -65,108 | 328,608 | -116,527 | -316,165 | -75,730 | -72,687 | 209,941 | |
| 123,539 | 185,721 | 203,063 | 229,972 | 256,962 | 241,870 | 341,482 | 180,129 | 259,878 | 286,809 | 294,208 | 202,773 | 265,528 | 220,320 | 70,201 | 73,799 | -59,366 | 149,336 | 249,592 | 194,365 | 452,042 | 774,463 | 937,068 | 343,467 | 235,614 | 677,557 | 626,772 |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.